Evidence map›Paper›PMID 23816330›Full record

ArticleTransplantation research2013

Extended pancreas donor program - the EXPAND study rationale and study protocol.

Andrea Proneth, Andreas A Schnitzbauer, Florian Zeman, Johanna R Foerster, Ines Holub, Helmut Arbogast, Wolf O Bechstein, Thomas Becker, Carsten Dietz, Markus Guba and 21 more

Registry-linked trialAbstract read
In one paragraph

Article in Transplantation research, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01384006 (EXTENDED PANCREAS DONOR PROGRAM - THE EXPAND STUDY), which is not on this map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01384006 unknown statusnot on this map

Extended pancreas donor program - the expand study

TypeobservationalSponsorUniversity of RegensburgRan2011 to 2014Enrolled110ConditionsPancreas Allograft Recipients w/wo Kidney Transplantation
3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Guideline
  2. Article
  3. Clinical use of donation after circulatory death pancreas for islet transplantation.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2021
    Article
  4. Article
  5. Article
  6. Pancreas transplantation: solid organ and islet.Cold Spring Harbor perspectives in medicine · 2014
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

31 authors.

Andrea PronethDepartment of Surgery, University Hospital Regensburg, Franz-Josef-Strauss-Allee 11, 93053 Regensburg, Germany. stefan.farkas@ukr.de.
Andreas A Schnitzbauer
Florian Zeman
Johanna R Foerster
Ines Holub
Helmut Arbogast
Wolf O Bechstein
Thomas Becker
Carsten Dietz
Markus Guba
Michael Heise
Sven Jonas
Stephan Kersting
Jürgen Klempnauer
Steffen Manekeller
Volker Müller
Silvio Nadalin
Björn Nashan
Andreas Pascher
Falk Rauchfuss
Michael A Ströhlein
Peter Schemmer
Peter Schenker
Stefan Thorban
Thomas Vogel
Axel O Rahmel
Richard Viebahn
Bernhard Banas
Edward K Geissler
Hans J Schlitt
Stefan A Farkas

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSimultaneous pancreas kidney transplantation (SPK), pancreas transplantation alone (PTA) or pancreas transplantation after kidney (PAK) are the only curative treatment options for patients with type 1 (juvenile) diabetes mellitus with or without impaired renal function. Unfortunately, transplant waiting lists for this indication are increasing because the current organ acceptability criteria are restrictive; morbidity and mortality significantly increase with time on the waitlist. Currently, only pancreas organs from donors younger than 50 years of age and with a body mass index (BMI) less than 30 are allocated for transplantation in the Eurotransplant (ET) area. To address this issue we designed a study to increase the available donor pool for these patients. METHODS/

designThis study is a prospective, multicenter (20 German centers), single blinded, non-randomized, two armed trial comparing outcome after SPK, PTA or PAK between organs with the currently allowed donor criteria versus selected organs from donors with extended criteria. Extended donor criteria are defined as organs procured from donors with a BMI of 30 to 34 or a donor age between 50 and 60 years. Immunosuppression is generally standardized using induction therapy with Myfortic, tacrolimus and low dose steroids. In principle, all patients on the waitlist for primary SPK, PTA or PAK are eligible for the clinical trial when they consent to possibly receiving an extended donor criteria organ. Patients receiving an organ meeting the current standard criteria for pancreas allocation (control arm) are compared to those receiving extended criteria organ (study arm); patients are blinded for a follow-up period of one year. The combined primary endpoint is survival of the pancreas allograft and pancreas allograft function after three months, as an early relevant outcome parameter for pancreas transplantation. DISCUSSION: The EXPAND Study has been initiated to investigate the hypothesis that locally allocated extended criteria organs can be transplanted with similar results compared to the currently allowed standard ET organ allocation. If our study shows a favorable comparison to standard organ allocation criteria, the morbidity and mortality for patients waiting for transplantation could be reduced in the future.

trial registrationTrial registered at: NCT01384006.

Identifiers

PMID23816330
PMCPMC3716891

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.